Emtricitabine (FTC) and lamivudine (3TC) are cytosine nucleoside analogues approved for use in HIV-1 infection. Both compounds select for the M184V/I mutation resulting in high-level resistance. This study compared the phenotypic resistance profiles of FTC and 3TC. Both compounds were tested against clinical samples submitted for routine resistance testing (PhenoSense™ ™ HIV assay). We evaluated 306 viruses with nucleoside reverse transcriptase inhibitor mutations (NRTI-R) and 100 viruses without resistance mutations (WT). Seventy-two percent had ≥1 thymidine analogue mutation (TAM), 21% had mixtures at M184, 14% had L74V and 7.5% had K65R. Results were expressed as fold change (FC) in 50% effective concentration compared with the NL4-3 reference. Concordance of FC was evaluated based on biological (99th percentile of the distribution of WT virus population) and clinical cutoffs (FC above which an optimal virological response declines).
Emtricitabine (FTC) and lamivudine (3TC) are cytosine nucleoside analogues with activity against HIV and hepatitis B virus. Both compounds are currently recommended as preferred nucleoside reverse transcriptase inhibitors (NRTI) as part of HAART regimens for the treatment of HIV (Department of Health and Human Services [DHHS], 2006) and both compounds select for the M184V/I mutations in the HIV reverse transcriptase (RT) in vitro and in vivo. Despite these similarities, differences have been observed in the pharmacodynamic and pharmacokinetic parameters of the two compounds. FTC was consistently more active than 3TC against HIV when compared side-by-side in the same assay (Schinazi, 2003) . Biochemical assays demonstrated that the triphosphate of FTC (FTC-TP) is incorporated ninefold more efficiently than the triphosphate of 3TC (3TC-TP) during HIV-1 RT-catalysed RNA-dependent DNA synthesis (Feng et al., 1999) , providing a mechanistic rationale for the increased potency observed in vitro. When compared directly in a monotherapy study, FTC was statistically superior to 3TC (-1.69 versus -1.48 decrease in HIV RNA for FTC versus 3TC, respectively; P=0.04) with regards to antiviral efficacy (Rousseau et al., 2003) . Genotypic analysis of plasma HIV obtained from patients following therapy, which included FTC or 3TC, demonstrated a significant decrease (P=0.009) in the incidence of the M184V mutation at time of failure amongst the FTC-treated patients versus 3TC-treated patients (McColl DJ, Lu B, Miller MD and Borroto-Esoda B . Pooled analysis of recent emtricitabine and lamivudine clinical trials reveals differences in rates of development of the M184V/I mutation. 10th European AIDS Conference (EACS) . Dublin, Ireland poster number PE7.3/17).
The superior activity of FTC over 3TC may be due to its enhanced pharmacokinetic profile. The intracellular half-life of FTC-TP is 39 h (Wang et al., 2004) , as compared with 19 h for 3TC-TP (Moore et al., 1999) , further supporting the once-daily dosing schedule of FTC.
HIV-1 phenotypic assays are routinely used in clinical practice in order to determine the most appropriate antiviral therapy. Whereas the biological and clinical cutoffs for 3TC in these assays have been established (Parkin et al., 2004) , there is limited data on these cutoffs for FTC. The purpose of this study was to establish a biological cutoff for FTC and to compare the phenotypic profiles of FTC and 3TC against NRTI-resistant strains of HIV. These data allow for the estimation of the clinical cutoff for FTC.
Methods
Phenotypic evaluation of the antiviral activity of FTC and 3TC was performed using the PhenoSense™ HIV assay (Monogram Biosciences Inc., South San Francisco, CA, USA) in the 293HEK cell line (Petropoulos et al., 2000) . A total of 406 clinical samples submitted for routine testing to Monogram Biosciences were evaluated: 306 viruses with NRTI mutations (NRTI-R) and 100 viruses without resistance mutations (WT). NRTI mutations were defined as M41L, K65R, D67N, T69ins, K70R, L74I/V, V75A/M/S/T, Y115F, Q151M, M184I/V, L210W, T215F/Y and K219E/N/Q/R. Viruses with M184V or I as full mutations were excluded, those with mixtures of M184V/I with wild-type were allowed. Results were expressed as fold change (FC) in 50% effective concentration (EC 50 ) compared with the NL4-3 reference. Concordance in FC, defined as agreement in resistance calls, was evaluated based on both biological (FTC and 3TC) and clinical cutoffs (3TC). The biological cutoff for the PhenoSense assay is defined as the 99th percentile of the distribution of a wild-type virus population (Parkin et al., 2004) . The clinical cutoff of 3.5-fold established for 3TC has been previously described and is defined as the FC above which the likelihood of an optimal virological response to 3TC begins to decline (Skowron et al., 1999) . Analysis of the effect of NRTI mutations on viral susceptibility to FTC and 3TC was also evaluated using pair-wise comparisons and plotted as bivariate scattergrams of log-transformed FC data, with linear regression lines for those isolates with NRTI mutations, with or without M184V/I.
Results
Mean EC 50 values obtained for FTC and 3TC against the NL4-3 reference laboratory strain of HIV were 1.01 ±0.14 and 2.79 ±0.37 μM, respectively. When tested against a panel of 100 WT clinical isolates, FTC and 3TC had identical mean FC values when compared with NL4-3 of 0.9 ±0.2. The biological cutoff established for both compounds against this panel of WT virus was 1.4-fold.
Among the 306 clinical isolates with NRTI resistance, the most common mutations observed were those associated with resistance to thymidine analogues (thymidine analogue mutations [TAMs] = any mutation at positions M41, D67, K70, L210, T215 or K219), with 222/306 (72%) isolates containing ≥1 TAM. Eighty-four of the 306 isolates (21%) contained mixtures of 184M/V or I, 44/306 (14%) contained the L74V mutation and 23/306 (7.5%) Figure 1 ). Similar results were obtained when the analysis was performed on this set of viruses with samples containing mixtures at position M184 being excluded. Amongst all 306 isolates, there was 95% concordance between resistance calls between FTC and 3TC when the biological cutoff of 1.4-fold was used, and 93% concordance when the clinical cutoff for 3TC (3.5-fold) was used for both drugs (Table 1) . Similar results were obtained when the analysis was performed on subsets of viruses containing mutations at positions M184, K65R and L74V and amongst viruses with TAMs. The susceptibility of viruses to inhibition by FTC and 3TC was further evaluated based on the class of mutations observed (Table 2) . Overall, no significant differences were observed between the median FC for FTC and 3TC against this panel of NRTI-resistant viruses: 2.7-and 2.3-fold for FTC and 3TC, respectively (P=0.44). The FC values for both FTC and 3TC increased and were above the clinical cutoff amongst subsets of viruses containing M184M/V or M184M/I mixtures (n=64; median FC 6-and 5.1-fold for FTC and 3TC, respectively; P=0.67), K65R (without M184 mixtures, n=19; respectively; P=0.49) or L74V (without M184 mixtures, n=37; median FC 3.7-and 3.3-fold, respectively; P=0.59). Whereas the median FC for both FTC and 3TC amongst viruses with ≥1 TAM was below the 3.5-fold clinical cutoff for 3TC (2.6-and 2.2-fold, respectively; P=0.6), there was an increase in median FC for both compounds with increasing numbers of TAMs with >70% of viruses with ≥4 TAMs having FC values greater than the 3.5-fold cutoff for both FTC and 3TC.
Discussion
The widespread use of antiretroviral therapy has led to the emergence of HIV variants with reduced susceptibility to antiretroviral agents (Richman, 1997) . Phenotypic and genotypic assays used to assess drug resistance have become standard of care when designing drug regimens for patients who have failed therapy. The interpretation of these assays is based on relevant thresholds that define the level of reduced susceptibility or number/type of mutations associated with less than optimal efficacy. Clinical cutoffs defined by results obtained from clinical trials provide the most relevant threshold. However, due to ethical considerations and limitations of clinical studies, clinical cutoffs may not be available for all anti-HIV compounds. In these cases, biological cutoffs, which are defined by the distribution of susceptibility amongst wild-type viruses, may be used.
In this study, we defined the biological cutoff for FTC and compared the phenotypic profiles of FTC and 3TC against a panel of viruses containing known resistance mutations. FTC and 3TC had an identical biological cutoff of 1.4-fold in these assays. Similarly, when tested against a panel of NRTI-resistant viruses, there were no significant differences between the two compounds regardless of mutation profile. Viruses containing mutations at positions M184V/I and K65R had the greatest FC, consistent with the resistance profile of FTC and 3TC (Feng et al., 2006) . These results are similar to those obtained by Ross et al. (2006) , which also found no differences in susceptibility to *Samples with M184V/I mix were excluded from the analysis; other nucleoside reverse transcriptase inhibitor-associated mutations (NRTI-R) may also be present. † Student's t-test, two sample assuming equal variance for fold change. TAM, thymidine analogue mutation. Table 2 . HIV susceptibility to emtricitabine and lamivudine by mutation class FTC and 3TC amongst viruses containing the NRTI mutations, K65R, L74V/I, and Q151M. However, whereas this previous study described differences between FTC and 3TC susceptibility amongst viruses containing multiple TAMs, our findings in this population do not support this interpretation. Although we did observe slightly higher levels of resistance for FTC compared with 3TC amongst viruses with ≥1 TAMs (2.6-versus 2.2-fold, respectively), these differences were not statistically significant. Importantly, both compounds demonstrated similar patterns of resistance amongst viruses containing TAMs with increasing FC values amongst viruses with increasing numbers of TAMs. The majority of viruses containing only one TAM remained susceptible to inhibition by FTC and 3TC, whereas the vast majority of viruses containing ≥4 TAMs had decreased susceptibility above the biological cutoff. The differences reported between these two studies may be due to the different populations of viruses evaluated, the different background mutations present between the two populations or the definitions (based on mutational pattern) used to define groups of viruses. Given the greater activity and longer intracellular half-life of FTC compared with 3TC, these small differences in FC are unlikely to be clinically significant. In a clinical study of FTC versus 3TC in treatment-experienced patients (Benson et al., 2004) , no differences were observed in the number of patients experiencing virological failure between the two arms; only the M184V mutation was significantly associated with virological failure in this study (Van der Horst C, Quinn JB, Hinkle J, Bae A, Borroto-Esoda K, Moxham C, Rousseau F. Predictors of virologic failure in HIV-1 infected adults on a stable lamivudine HAART regimen. 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 2002 . Poster H-2050 .
In summary, FTC and 3TC exhibited similar biological cutoffs against wild-type clinical isolates of HIV-1 and had comparable FCs in activity when evaluated against viruses containing NRTI mutations. Although a direct comparison of clinical cutoffs for FTC and 3TC can not be performed, these results strongly suggest that similar genotypic interpretation algorithms and phenotypic cutoffs may be applied to both drugs.
